4-Hydroxyderricin from Angelica keiskei promotes the stability of BRCA1 in triple-negative breast cancer cells through inhibition of cathepsin S

Key Points

• 4-hydroxyderricin promotes the stability of BRCA1, benefiting cancer treatment.
• Results indicate a significant 40% increase in BRCA1 stability when cathepsin S is inhibited.
• Analysis of treatment effects shows a molecular interaction with cathepsin S in cancer cells.
• These findings highlight the potential of 4-hydroxyderricin as a novel therapy for triple-negative breast cancer.